Alberto Hernando-Calvo

11PUBLICATIONS
124CO-AUTHORS
Molecular targetsPredictive and prognostic markersChemotherapyInnate immunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 08, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy.

|May 08, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Dec 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.

Elena Garralda, Charles Abbott, Alma Calahorro

|Jul 11, 2025
Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.

Alberto Hernando-Calvo, Richard D Carvajal, Paul K Paik

|Aug 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.

Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús

Pageof 2

Frequent Collaborators

4 joint publications

Philippe L Bedard

3 joint publications

Elena Garralda

2 joint publications

Rachel Salazar

2 joint publications

Dan P Zandberg